4521 Kaken Pharmaceutical
- 3451.0
- +8.0+0.23%
Kaken Pharmaceutical News
Express News | Kaken Pharmaceutical Co - to Invest About 10 Bln Yen to Build a New Agrochemicals Plant in Shizuoka, Japan
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1815＞ Tekken 2651 3005 ＜1938＞ Nichiritech 1173 1343 ＜1964＞ Chugai Reactor 3145 3545 ＜1979＞ Taiisha 4710 4915 ＜2001＞ Nippun
List of Unrivaled Stocks (Part 2) [Ichimoku Equilibrium Chart/Kumoku Stock List]
○List of Unbroken Stocks Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime ＜1786＞ Oriental Shiraishi 355 397.5 380 ＜1803＞ Shimizu Ken 912 947.5 953 ＜1812＞ Kashima 2715 3028.25 2888.5 ＜1950＞ Japan
Express News | Kaken Pharmaceutical 2023/24 Group Net Profit 8.03 Bln Yen (+47.5 %), 2024/25 Forecast Profit 5.60 Bln Yen (-30.2 %)
Express News | Kaken Pharmaceutical 2023/24 Group Recurring Profit 9.95 Bln Yen (+14.0 %), 2024/25 Forecast Profit 7.80 Bln Yen (-21.6 %)
Kaken Pharmaceutical Sees FY Net Y5.60B
Kaken Pharmaceutical Co. Ltd. also released the following forecasts: GROUP Year Ending Mar 2025 Revenue Y75.10 bln Operating Profit Y7.40 bln Pre
Kaken Pharmaceutical: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Kirin HD, Takeda Pharmaceutical, Sumitomo, SoftBank (9th)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/9 (Thu) ＜1375＞Snow Country Maitake ＜1720＞Tokyu Construction＜1738＞Nittoh ＜1764＞Kudo Construction＜1788＞Santo Kogyo ＜1799＞Daiichi Kenset＜1869＞Meikouken ＜1870＞Yahagi Kenset＜1929
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○List of trading stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1333＞ Maruha Nichiro 3083 2918 ＜1887＞ Japan Land Development 520 496 ＜1950＞ Nippon Densetsu 2152 2046 ＜2264 ＞ Morinaga Milk 3105 2945 ＜2270＞ Snow Brand Meg 2
List of Yunlou stocks [Ichimoku equilibrium table/ Yunlou stock list]
○Kumojo Stock List Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime ＜1720＞ Tokyu Construction 839 829.75 820.5 ＜1979＞ Taikisha 4685 4652.5 4467.5 ＜2461＞ Fan Review 402 401 400 ＜2733＞ New
List of Unrivaled Stocks (Part 1) [Ichimoku Equilibrium Chart/Kumoku Stock List]
○Kumojo Stock List Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime ＜1976＞ Meisei Kogyo 1231 1230.5 1178.5 ＜5970＞ G-TEKT 2073 2014.25 1886.5 ＜6740＞ JDI 22 21.75 20 ＜7453＞ Good Product Plan 2338
Convertible Stock List (Part 3) [Parabolic Signal Convertible Stock List]
○ List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜2922＞ Natori 2114 2179 ＜2931＞ Euglena 605 641 ＜3002＞ Gunze 5420 5680 ＜3036＞ Alconix 1435 1496 ＜3087＞ Doutor Day Less
Transfer of the rights of “Melislon” and “Mionar” in Japan to Kinkaku Pharmaceutical
For printing 2024/3/29, Eisai Co., Ltd. (Headquarters: Tokyo; Representative Executive Officer and CEO: Haruo Naito) is pleased to announce that it has now signed an agreement to transfer domestic rights to the vertigo and balance disorder treatment agent “Melisone” (generic name: betahistine mesylate) and the muscle tone improving agent “Mional” (generic name: eperisone hydrochloride) to Kagaku Pharmaceutical Co., Ltd. (Headquarters: Tokyo, hereinafter referred to as Kaken Pharmaceutical). “Merislon” and “Mionard” are those in Japan
Care net, Tohokushinsha, etc. [5% rule]
＜2121＞MIXI Co., Ltd. Kenji Kasahara Stock Ownership Ratio 42.19% → 44.11% Reporting Obligation Date 2024/03/19 ＜2150＞Care Net Co., Ltd. Medical Incubator Japan Stock Holding Ratio 17.57% → 17.01% Reporting Obligation Date 2024/03/21 ＜2329＞Tohoku Shinsha Co., Ltd. 3D Investment Partners Private Limited (3D Inns)
Jacossen Pharmaceutical (02633) completed the placement of a total of 66 million shares
Jacochen Pharmaceutical (02633) issued an announcement. All conditions contained in the placement agreement have been met, and the placement has been completed on 20...
Jacoson Pharmaceuticals (02633) plans to discount approximately 1.64% of the placement for a total of 66 million shares to raise HK$38.8 million
Zhitong Finance App News, Jacochen Pharmaceutical (02633) issued an announcement. On February 19, 2024, the company entered into a placement agreement with the placement agent. The company appointed the placement agent to place a total of 66 million shares at a price of HK$0.60 per share (or the number of carriers agreed in writing between the company and the placement agent) at a price of HK$0.60 per share. The placement price of each placed share was HK$0.60 per share, compared to the closing price of the share on February 19 HK$0.61 discounted by approximately 1.64%, Assuming that all of the shares to be placed are sold
Kaken Pharmaceutical 1H Net Y4.07B Vs Net Y5.96B
Kaken Pharmaceutical Co. Ltd. (4521.TO) Japan 1st Half Ended September 30 GROUP 2023 2022 Revenue Y36.17 bln Y36.82 bln Operating Profit Y5.51 bln
Kaken Pharmaceutical's Attributable Profit Drops 13.7% in Fiscal Q1 Due to Higher Expenses
Kaken Pharmaceutical's (TYO:4521) profit attributable to owners of the parent fell 13.7% to 2.51 billion yen in the fiscal first quarter ended June 30, from 2.91 billion yen a year ago, mainly due to
Kaken Pharmaceutical Sees FY Net Y6.70B
Kaken Pharmaceutical Co. Ltd. also released the following forecasts: GROUP Year Ending Mar 2024 Revenue Y73.10 bln Operating Profit Y7.60 bl
Kaken Pharmaceutical Sees FY Net Y6.10B
Kaken Pharmaceutical Co. Ltd. also released the following forecasts: GROUP Year Ending Mar 2023 Revenue Y73.50 bln Operating Profit Y7.50 bl
Analysis
Price Target
No Data
